Partners in the Fight
The eventual elimination of tuberculosis as a public health threat is a global effort that requires global commitment. To achieve this goal, there must be both investment in and support for the implementation of current TB control strategies, as well as research and development of new tools to combat the disease. In particular, new, more effective drugs, diagnostics and vaccines are crucial. We must improve current diagnostic and treatment strategies while also investing in long-term prevention through new vaccines.
A number of research, advocacy and implementing organizations are making great strides in developing and advocating for new tools to combat TB.
The Global Alliance for TB Drug Development (TB Alliance) is developing new, affordable TB drugs that will shorten treatment time, work against drug-resistant TB, be compatible with HIV antiretrovirals and improve treatment of latent TB.
The Foundation for Innovative New Diagnostics (FIND) is developing rapid, accurate and affordable TB tests and point-of-care diagnostics to more efficiently detect TB, especially drug-resistant forms of the disease.
The U.S. Centers for Disease Control and Prevention (CDC) Division of Tuberculosis Elimination (DTBE) promotes health and quality of life by preventing, controlling and eventually eliminating tuberculosis from the United States, and by collaborating with other countries and international partners in controlling global tuberculosis.
The National Institute of Allergy and Infectious Diseases at the U.S. National Institutes of Health conducts research to better understand, treat and prevent tuberculosis.
The United States Agency for International Development (USAID) works with 28 countries to improve TB services.
The World Health Organization’s (WHO) Global TB Programme advances universal access to TB prevention, care and control; guides the global response to threats; and promotes innovation.
The European Commission’s Research Framework Programme 7 funds research aimed at combating HIV/AIDS, malaria and tuberculosis.
The Stop TB Partnership Working Group on New Vaccines facilitates the development of new, more effective TB vaccines by promoting collaboration and coordination amongst multiple stakeholders. The Working Group serves as the mechanism of exchange and dialogue between the Stop TB Partnership and the research community, provides a forum to discuss challenges to TB vaccine development and identify solutions, and builds consensus on key issues and questions related to TB vaccine research and development.
ACTION is a global partnership of advocacy organizations working to influence policy and mobilize resources to fight diseases of poverty and improve equitable access to health services. They work across five continents in both donor and high burden countries.
Treatment Action Group (TAG) has a TB/HIV Project that works to strengthen global and U.S.-focused advocacy to increase funding and ensure ambitious and improved research, programs and policy to ensure universal access to quality services for people with TB and HIV.
The Global Health Technologies Coalition (GHTC) is a group of more than 25 nonprofit organizations working to increase awareness of the urgent need for technologies that save lives in the developing world.